Tango Therapeutics, Inc. recent senior management appointments: Marc Rudoltz, M.D., as Chief Medical Officer. Dr. Rudoltz has more than 20 years' experience leading all phases of clinical drug development. As the principal of MSR Healthcare Consultants LLC, Dr. Rudoltz served as Chief Medical Officer for a number of companies including Deciphera Pharmaceuticals, and Constellation Pharmaceuticals and as a clinical consultant for Blueprint Medicines. In these roles, Dr. Rudoltz led teams to start and accelerate the clinical development of a number of targeted small molecule anti-cancer agents including Qinlock?, Aykavit?, Gavreto?, and pelabrisib. Previously, he worked in clinical development roles for several companies, including Novartis where he played key roles in the development and commercialization of Gleevec? and Tasigna?. Dr. Rudoltz obtained his B.S. in Chemical Biology from the Massachusetts Institute of Technology and M.D. from SUNY-Upstate Medical University.